The incidence of recurrent Clostridioides difficile infection was lower among at-risk patients on antibiotics for other ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

Dr Derbyshire explained that mint tea contains active compounds such as rosmarinic acid and menthol, which “exhibit ...

Teams from various departments have sprung into action to prevent and control vector-borne diseases like dengue, malaria, and ...

A popular beverage has been linked to a host of health advantages, including the potential to reduce blood pressure and ...

A popular beverage has been linked to a host of health advantages, including the potential to reduce blood pressure and ...

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

Adults with congenital adrenal hyperplasia treated with an oral nonsteroidal drug saw continued disease control with reduced ...

Chronic inflammation, already tied to heart disease and cancer, may also worsen the emotional toll of poor sleep. A new UCLA ...

His suggested timeline for green-lighting psychedelic therapy surprised even the most bullish supporters of the drugs.

OKYO Pharma (NASDAQ:OKYO) stock jumped 14% Wednesday after announcing encouraging Phase 2 clinical trial results for urcosimod, their investigational drug aimed at neuropathic corneal pain (NCP). The ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...